Eli Lilly & Co. (LLY) Social Stream



Eli Lilly & Co. (LLY): $323.00

5.38 (+1.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ELI LILLY & Co (LLY) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering LLY.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-27 12 $315 $183 $272.666 $286.37 -4.79%
2021-11-19 12 $315 $183 $275.615 $286.37 -3.76%
2021-12-08 12 $315 $183 $278.615 $286.37 -2.71%
2021-12-15 13 $315 $250 $285.307 $286.37 -0.37%
2021-12-16 13 $335 $250 $290.615 $286.37 1.48%
2021-12-20 13 $335 $265 $299.076 $286.37 4.44%
2022-01-12 13 $335 $265 $299.846 $286.37 4.71%
2022-02-04 12 $335 $265 $299.846 $286.37 4.71%
2022-02-14 12 $335 $265 $299.307 $286.37 4.52%
2022-02-24 12 $335 $265 $298.615 $286.37 4.28%
2022-03-10 12 $335 $265 $297.714 $286.37 3.96%
2022-03-17 12 $335 $265 $298.785 $286.37 4.34%

The Trend in the Analyst Price Target


Over the past 23 months, LLY's average price target has gone up $138.21.

Over the past 50 weeks, LLY's average upside potential has been 9.48%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-15 21 252 175 213.410 196.21 8.77%
2021-09-11 23 315 193 262.240 239.50 9.49%
2021-09-20 22 315 202 265.880 231.64 14.78%
2021-11-23 12 315 183 278.615 261.96 6.36%
2022-02-04 12 335 265 299.846 242.27 23.77%

LLY Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.17 11 0 1 0 0 12

The Trend in the Broker Recommendations


Over the past 23 months, LLY's average broker recommendation rating improved by 0.83.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LLY as an investment opportunity.

  • LLY has a higher average analyst price target than 1218.55% of all US stocks.
  • In terms of how ELI LILLY & Co fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 39.89% of that group.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ELI LILLY & Co's number of analysts covering the stock is greater than 1129.31% of them.
  • In the context of stocks in the mega market cap category, ELI LILLY & Co's variance in analysts' estimates is lower than -289.84% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ELI LILLY & Co are JNJ, ABT, and ABBV.

Is LLY a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.427 seconds.